Plasmodium falciparum antigenic epitopes (Pf epitopes)

Plasmodium falciparum antigenic epitopes are specific molecular regions on the proteins of the P. falciparum parasite that are recognized by the host's immune system, particularly by antibodies and T-cells (Crompton et al., 2014). These epitopes are located on various stage-specific proteins, such as the circumsporozoite protein (CSP) on sporozoites, merozoite surface proteins (MSPs) on blood-stage parasites, and P. falciparum erythrocyte membrane protein 1 (PfEMP1) on the surface of infected red blood cells (Draper et al., 2018). They are the primary focus of malaria vaccine development and monoclonal antibody therapies, which aim to elicit or provide protective immunity by blocking the parasite's ability to invade host cells or by promoting its destruction (Gaudinski et al., 2021). For instance, the RTS,S/AS01 and R21/Matrix-M vaccines target epitopes within the central repeat region of the CSP to prevent liver-stage infection (WHO, 2023). However, the high degree of genetic polymorphism and antigenic variation within these epitopes allows the parasite to evade immune detection, presenting a major challenge for creating a universal vaccine (Amulic et al., 2012). Therapeutic strategies often involve targeting conserved epitopes or using multi-antigen approaches to overcome this diversity and provide broad protection against different parasite strains (Duffy et al., 2012).

Other names

Malaria antigensPlasmodium falciparum surface antigensPlasmodium falciparum vaccine candidatesPf antigens

Induction of neutralizing antibodies that inhibit parasite motility and host cell invasion, and activation of cellular immune responses to clear infected cells.